Welcome to our dedicated page for Cambiar Aggressive Value ETF news (Ticker: CAMX), a resource for investors and traders seeking the latest updates and insights on Cambiar Aggressive Value ETF stock.
Camurus AB (NASDAQ: CAMX) is a science-driven biopharmaceutical innovator specializing in long-acting therapies for chronic conditions. This page provides authorized news updates, press releases, and regulatory filings directly from the company and verified sources.
Investors and healthcare professionals will find timely updates on clinical trial progress, product approvals, and strategic partnerships. Our curated feed includes developments in opioid dependence treatments, acromegaly therapies, and advancements in FluidCrystal® drug delivery technology.
Key content categories include quarterly financial results, research milestones, manufacturing updates, and market expansion initiatives across Europe, Australia, and global markets. All information is sourced from official company communications and regulatory disclosures.
Bookmark this page for structured access to CAMX developments that matter to stakeholders. For comprehensive understanding of Camurus' scientific approach, review our company profile section alongside these real-time updates.
Camurus (NASDAQ STO: CAMX) has received a positive recommendation from the European Medicines Agency's CHMP for market authorization of Oczyesa®, a monthly octreotide depot treatment for adult acromegaly patients. The recommendation is supported by comprehensive clinical data from seven studies, including two Phase 3 trials.
The ACROINNOVA 1 study showed Oczyesa achieved higher normalization rates of insulin growth-factor-1 (IGF-1) levels versus placebo. ACROINNOVA 2 confirmed sustained IGF-1 improvements and demonstrated enhanced symptoms, quality of life, and treatment satisfaction over 52 weeks compared to standard care. Common side effects included gastrointestinal, nervous system, and hepatobiliary disorders.
A final European Commission decision on marketing authorization is expected in mid-2025.
Camurus (NASDAQ: CAMX) announced positive final results from the 52-week Phase 3 ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients. The study met its primary safety endpoint, showing a profile consistent with standard-of-care. Key findings include:
1. Increased biochemical response rates vs. baseline
2. Continuous improvement in acromegaly symptoms and quality of life
3. Well-tolerated treatment with no new safety signals
The study included 135 patients, with 81 new and 54 roll-over patients. Results showed a 12.7% increase in treatment response rates overall, and 22.8% in new patients. Regulatory reviews are ongoing in the US and EU, with an FDA decision expected by October 21, 2024.
Camurus has announced a new publication in JAMA Network Open, detailing a post hoc analysis from a 24-week Phase 3 study comparing weekly and monthly subcutaneous buprenorphine injections (Buvidal®/Brixadi®) to daily sublingual buprenorphine/naloxone. The study involved 428 participants, with 123 showing baseline fentanyl use. Results showed that the mean percentage of fentanyl-negative urine samples was higher in the SC-BPN group (74%) compared to the SL-BPN/NX group (61.9%). Withdrawal symptoms and cravings decreased in fentanyl-positive patients following treatment initiation. Safety profiles were consistent with known data, with mild to moderate injection site reactions observed. The publication underscores the effectiveness of extended-release buprenorphine in treating opioid dependence even in patients using fentanyl.
Cambiar Investors announces the launch of the Cambiar Aggressive Value ETF (NYSE Arca: CAMX), transitioning from the Cambiar Aggressive Value Fund. This actively managed ETF focuses on a concentrated portfolio of 20-30 high-conviction stocks, aiming for strong absolute returns and referencing the Russell 1000 Value Index. Cambiar President Brian Barish highlights value investing's resurgence, correlating with the higher cost of capital and growth stock performance challenges. Investors may find CAMX appealing as market leadership shifts towards value.
